AstraZeneca oral diabetes treatment gets European marketing approval
1st Feb 2019 15:02
(Sharecast News) - AstraZeneca said on Friday that the European Medicines Agency (EMA) has recommended marketing authorisation for its Forxiga treatment for use as an oral adjunct treatment to insulin in adults with type-1 diabetes.
Read moreFriday broker round-up
25th Jan 2019 13:21
(Sharecast News) - Fresnillo: UBS upgrades to buy with a target price of 1,100p.
Read moreMonday broker round-up
14th Jan 2019 13:44
(Sharecast News) - Next: Credit Suisse downgrades to underperform with a target price of 4,800p.
Read moreAstraZeneca announces structural changes, hires Jose Baselga
7th Jan 2019 16:04
(Sharecast News) - AstraZeneca announced a number of organisational changes on Monday, which it said would support its "continued scientific innovation" and commercial success in the main therapy areas as it entered a new phase in its strategic development.
Read moreAstraZeneca receives EU approval for Bevespi Aerosphere inhaler
20th Dec 2018 14:01
(Sharecast News) - FTSE 100 pharma giant AstraZeneca said its chronic obstructive pulmonary disease treatment Bevespi Aerosphere was approved for use in the EU.
Read moreAstraZeneca upbeat on positive results from three drug trials
20th Dec 2018 07:25
(Sharecast News) - AstraZeneca announced a slew of positive drug trial results on Thursday, first reporting that the Phase III OLYMPUS and ROCKIES trials for roxadustat had each met their primary efficacy endpoints, for the treatment of patients with anaemia in chronic kidney disease (CKD) that were either non-dialysis-dependent or dialysis-dependent, respectively.
Read moreAstraZeneca gets China approval for roxadustat
18th Dec 2018 11:15
(Sharecast News) - AstraZeneca's roxadustat drug has been approved in China for the treatment of anaemia in chronic kidney disease patients on dialysis.
Read moreAstraZeneca's Imfinzi fails to reach endpoint in difficult trial
7th Dec 2018 07:24
(Sharecast News) - AstraZeneca and its global biologics research and development arm MedImmune announced overall survival results for the Phase III EAGLE trial of Imfinzi (durvalumab) on Friday.
Read moreAstraZeneca offloads ciclesonide rights to Covis in $350m deal
6th Dec 2018 07:23
(Sharecast News) - AstraZeneca has completed an agreement with Covis Pharma to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis.
Read moreAstraZeneca offloads rights to Nexium and Vimovo
3rd Dec 2018 07:25
(Sharecast News) - AstraZeneca has completed an agreement to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights - excluding the US and Japan - to Vimovo (naproxen/esomeprazole), to Grunenthal, it announced on Monday.
Read moreUS FDA grants orphan status for AstraZeneca's Fasenra
26th Nov 2018 07:18
(Sharecast News) - AstraZeneca on Monday said its Fasenra treatment for the autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA) had been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA).
Read moreMonday broker round-up
19th Nov 2018 12:13
(Sharecast News) - Sainsbury: Berenberg reiterates buy with a target price of 369p.
Read moreBP, Astra, NMC, Lloyds among Barclays' European top picks
19th Nov 2018 08:52
(Sharecast News) - Although poor investor sentiment, "idiosyncratic risks" including Brexit, Italian and German politics, ECB and European parliamentary elections next year have weighed on European stock, Barclays expects to see some of the losses to be recouped into the year end, with 19 selected as "top picks".
Read moreAstraZeneca offloading rights to two non-core drugs
30th Oct 2018 07:12
(Sharecast News) - AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights - excluding the US and Japan - to Vimovo (naproxen/esomeprazole), to Grünenthal, it announced on Tuesday.
Read moreTuesday broker round-up
23rd Oct 2018 12:53
(Sharecast News) - CYBG: Barclays initiates underweight with a target price of 280p.
Read more